Ipsen

This study tests a daily pill called elafibranor in adults with primary biliary cholangitis (PBC) whose current treatment isn't working well enough or causes side effects. The main goal is to see if elafibranor can bring a key liver enzyme (ALP) back to normal levels. About 69 pa…

This study tests a drug called elafibranor in 68 adults with primary sclerosing cholangitis (PSC), a rare liver disease that damages bile ducts. The main goal is to check the drug's safety and side effects compared to a placebo. Researchers will also look at blood tests to see if…

This study tracks adults with advanced kidney cancer who are receiving a combination of two drugs, cabozantinib and nivolumab, as their first treatment. Researchers are observing how long patients live and how long the cancer stays under control in everyday medical practice. The …

This study tests a daily pill called elafibranor in 18 Japanese adults with primary biliary cholangitis (PBC), a chronic liver disease. The goal is to see if the drug can lower two key markers of liver damage (ALP and bilirubin) over a year, with long-term follow-up. Participants…

This study aims to see how well the drug tazemetostat works in adults with a slow-growing blood cancer called follicular lymphoma that has come back or not responded to at least two prior treatments. Participants will take tazemetostat as prescribed by their doctor in routine car…

This study tests a new drug called elafibranor for people with primary biliary cholangitis (PBC), a rare liver disease that can lead to scarring and liver failure. The trial includes 161 adults who did not get better with or could not take the standard medicine. The goal is to se…

This study tests whether Dysport injections can prevent chronic migraine in adults who have headaches at least 15 days per month. About 759 participants will receive either Dysport or a placebo injection into head, neck, and shoulder muscles. The goal is to see if Dysport reduces…

This study tests whether Dysport, a botulinum toxin type A injection, can prevent episodic migraines (fewer than 15 headache days per month) in adults. About 751 participants will receive either Dysport or a placebo injected into head, neck, and shoulder muscles over 24 weeks, fo…

This study tests a new medication called IPN10200 to improve the appearance of moderate to severe frown lines, forehead lines, and crow's feet in adults aged 18 to 65. Researchers will compare different doses of IPN10200 to a placebo and to an existing treatment (Dysport) to find…

This study follows about 1,058 adults who have had their first stroke to see how many develop muscle stiffness (spasticity) that could benefit from medication. Researchers will track participants for one year after their stroke. The goal is to create a standard guideline for doct…

This study follows 113 adults with arm stiffness from brain injuries who are receiving botulinum toxin injections in routine care. Researchers measure how the treatment affects daily tasks for both patients and their caregivers over time. The goal is to understand real-world bene…

This study watches how patients with advanced kidney cancer are actually treated with the drug cabozantinib (Cabometyx), either alone or with nivolumab, in everyday medical practice. Researchers will track dosing changes, treatment delays, and quality of life in 150 adults in Bel…

This study follows 450 premenopausal women with early-stage, hormone-sensitive breast cancer in Italy. Researchers want to see how adding the drug triptorelin to standard hormone therapy affects quality of life and hormone levels. The goal is to better understand the real-world i…

This study looks at a rare inherited liver disease called PFIC, which causes severe itching and liver damage. Researchers compared patients who took the drug odevixibat to similar patients who did not receive the drug, using data from a patient registry. The goal was to see if od…

This study watches 224 adults with advanced kidney cancer who are already taking cabozantinib (alone or with nivolumab) as their first treatment. Researchers track how often patients need to lower doses, pause, or stop treatment due to side effects. No new drugs are tested; the g…